EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
Medical Devices Regulation - Hazardous Substances
EU. Hazardous Substances for Purposes of Medical Devices Regulation 2017/745/EU, 5 May 2017, as amended by Regulation 2020/561/EU, 24 April 2020
This list contains hazardous substances for purposes of the Medical Devices Regulation (MDR), based on the legislation's Annex I general safety and performance requirements, including for chemical, physical and biological properties. Specifically, the non-exhaustive database is derived from: Table 3 of Annex VI to CLP, REACH Candidate List of SVHCs, and Directive 2000/54/EC's Annex III (Biological Agents list).
Last updated 11 listopada 2024. Database contains 4918 unique substances/entries.
Filter the list
|
213-482-4
|
957-51-7
|
Acute Tox. 4 |
Details | |||
|
DIETHYLDIMETHYLAMMONIUMHYDROXIDE
|
419-400-5
|
95500-19-9
|
Acute Tox. 4; Skin Corr. 1A |
Details | ||
|
306-004-1
|
95465-89-7
|
Press. Gas; Flam. Gas 1; Carc. 1A; Muta. 1B |
Details | |||
|
ESACURE TZT 100
|
403-150-9
|
954-16-5
|
Acute Tox. 4; Eye Irrit. 2 |
Details | ||
|
305-975-9
|
95371-08-7
|
Carc. 1B |
Details | |||
|
305-974-3
|
95371-07-6
|
Carc. 1B |
Details | |||
|
305-972-2
|
95371-05-4
|
Carc. 1B |
Details | |||
|
305-971-7
|
95371-04-3
|
Carc. 1B |
Details | |||
|
-
|
95342-41-9
|
END Endocrine disrupting properties (Article 57(f) - human health) |
Details | |||
|
-
|
953-17-3
|
Acute Tox. 3 |
Details | |||
|
680-302-2
|
95266-40-3
|
STOT RE 2; Skin Sens. 1B |
Details | |||
|
804-373-8
|
951659-40-8
|
Acute Tox. 4; STOT RE 2 |
Details | |||
|
(2-BENZOTHIAZOLYLTHIO)BERNSTEINSÄURE; BTTBS; HALOX 650; IRGACOR 252
|
401-450-4
|
95154-01-1
|
Skin Sens. 1 |
Details | ||
|
C.I. REACTIVE BROWN 44
|
400-430-2
|
95078-21-0
|
Skin Sens. 1 |
Details | ||
|
A complex combination of hydrocarbons obtained by distillation of the polymerized C8 through C12 fraction from steam-cracked petroleum distillates. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C8 through C12.
|
305-750-5
|
95009-23-7
|
Carc. 1B; Muta. 1B; Asp. Tox. 1 |
Details | ||
|
213-449-4
|
950-37-8
|
Acute Tox. 2; Acute Tox. 4 |
Details | |||
|
213-447-3
|
950-10-7
|
Acute Tox. 1; Acute Tox. 2 |
Details | |||
|
202-467-8
|
95-95-4
|
Acute Tox. 4; Eye Irrit. 2; Skin Irrit. 2 |
Details | |||
|
202-464-1
|
95-92-1
|
Acute Tox. 4; Eye Irrit. 2 |
Details | |||
|
202-461-5
|
95-87-4
|
Acute Tox. 3; Skin Corr. 1B |
Details | |||
|
202-453-1
|
95-80-7
|
Carc. 1B; Muta. 2; Repr. 2; Acute Tox. 3; Acute Tox. 4; STOT RE 2; Skin Sens. 1 |
Details | |||
|
202-453-1
|
95-80-7
|
C Carcinogenic (article 57a) |
Details | |||
|
202-448-4
|
95-76-1
|
Acute Tox. 3; Eye Dam. 1; Skin Sens. 1 |
Details | |||
|
202-442-1
|
95-70-5
|
Acute Tox. 3; Acute Tox. 4; Skin Sens. 1 |
Details | |||
|
202-441-6
|
95-69-2
|
Carc. 1B; Muta. 2; Acute Tox. 3 |
Details | |||